Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KW-120-94-1
- Development stage
- Preclinical
- Lead developer
- University of Arizona
- Modality
- Small Molecules
01
Overview
KW-120-94-1 is a synthetic analog of the natural product withaferin A, which is derived from the plant *Withania somnifera* (Ashwagandha). Developed and studied at the University of Arizona, this compound has demonstrated potent anti-cancer activity in preclinical models of pancreatic cancer, including poorly-differentiated (Panc-1), moderately differentiated (MiaPaca-2), and well-differentiated (BxPC-3) cell lines. Its mechanism of action involves the up-regulation of the mitogen-activated protein kinase (MAPK) signaling pathway and the glutathione metabolic pathway, leading to increased cellular stress and the induction of apoptosis. KW-120-94-1 has shown growth inhibitory effects with IC50 values ranging from 0.45 to 2.25 µM across different pancreatic cancer cell lines, characterized by morphological changes and PARP cleavage.
- Other names
- Withaferin A analog
02
Targets
HSPA1B (Heat shock protein family A member 2)GPX2 (Glutathione peroxidase 2)HSPA1A (HSP70-1A)GPX3 (Glutathione peroxidase 3)GCL (Gamma-glutamylcysteine Synthetase)JUN (Transcription factor Jun)
Beyond the preview
Go deeper on KW-120-94-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KW-120-94-1.